Short answer
Fulcrum Therapeutics, Inc. (FULC) filed an 8-K current report with the SEC on August 17, 2026 reporting Item EX-99.1 (Exhibit EX-99.2), Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Slate shares in the Concurrent Investment to be issued through private placements.
Fulcrum Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Slate shares in the Concurrent Investment to be issued through private placements
- Securities issuance relies on Securities Act Section 4(a)(2) and/or Regulation D exemptions
- Exempt offering structure limits registration requirements but restricts public offering availability
- Transaction involves Fulcrum and Slate securities, with no public offer or solicitation in the filing
Item 7.01 · Regulation FD Disclosure
- Proposed Fulcrum-Slate merger remains subject to stockholder approval, regulatory clearances and other closing conditions
- Transaction contemplates Slate private-placement financing, with proceeds intended to support the combined company
- Combined company is projected to fund operations into 2029, but additional financing may still be required
- Fulcrum stockholder ownership and potential cash distributions depend partly on net cash at closing
- Investors should await the Form S-4 proxy statement for exchange-ratio, financing and transaction-risk details
Item EX-99.1 · Exhibit EX-99.2
- All-stock merger shifts Fulcrum into Slate Medicines, focusing the public company on migraine therapeutics
- Fulcrum holders expected to own 5.0%; Slate holders 95.0%, subject to adjustment based on Fulcrum net cash
- Estimated $270.0 million cash dividend to pre-merger Fulcrum stockholders, with approximately $20.3 million contributed at closing
- $245 million oversubscribed private placement expected to fund operations into 2029 and advance SLTE-1009 clinical studies
- Fourth-quarter 2026 closing requires shareholder approvals, SEC registration effectiveness, and antitrust clearance
Other items in this filing:
- Item 3.02: Unregistered Sales of Equity Securities
- Item 5.01: Changes in Control of Registrant
- Item 5.02: Departure/Election of Directors or Officers
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Fulcrum Therapeutics, Inc. 8-K filings
Get the next FULC 8-K as it lands
Follow FULC for push alerts, or ask the research agent what this filing means.